AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Aurinia Pharmaceuticals Soars 24% on Positive LUPKYNIS Study Results
Generated by AI AgentAinvest Pre-Market Radar
Friday, May 23, 2025 5:13 am ET1min read
Aurinia Pharmaceuticals Inc. (AUPH) reported a 24% increase in total revenue for Q1 2025, reaching $62.5 million compared to $50.3 million in Q1 2024.
Aurinia Pharmaceuticals announced new findings from a post-hoc analysis of the Phase 3 AURORA 1 study, demonstrating that lupus nephritis patients receiving triple immunosuppressive therapy with LUPKYNIS achieved significantly lower proteinuria levels compared to the control group. This suggests that LUPKYNIS-based therapy could lead to better long-term kidney health and reduced cardiovascular risk for patients, reinforcing its critical role in improving health outcomes for lupus nephritis patients.
The findings, presented on May 22, underscore the potential of LUPKYNIS in improving kidney health outcomes for lupus nephritis patients. The company's primary product, LUPKYNIS, is a second-generation calcineurin inhibitor used as an immunosuppressant to treat lupus nephritis, a severe kidney inflammation caused by systemic lupus erythematosus.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Aeva Technologies Inc. plunged 5.95% on Dec. 24 2025 as tech sector sell-offs and shifting investor sentiment drove decline.
Dec.24 2025
SEALSQ plunges 5.88% amid heightened market volatility and sector pressures
Dec.24 2025
Vestis shares fall 6.30% in pre-market trading as cautious investor sentiment ahead of holidays sparks selloff.
Dec.24 2025
Nvidia shares rose 3.01% pre-market on December 24 2025 signaling renewed investor confidence amid evolving market dynamics.
Dec.24 2025
ECARX Holdings plunges 8.33% in pre-market trading on investor caution ahead of earnings report and sector volatility
Dec.23 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet